EICHORPublic-registry site landscape for NCT03592264, “A Phase I/II Study of OBI-3424 in Subjects with Advanced Solid Tumors”, a Solid Tumor study sponsored by OBI Pharma, Inc. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT03592264 (registry record) |
| Study title | A Phase I/II Study of OBI-3424 in Subjects with Advanced Solid Tumors |
| Sponsor | OBI Pharma, Inc |
| Condition(s) | Solid Tumor; Pancreatic Adenocarcinoma |
| Phase | PHASE1 / PHASE2 |
| Listed sites | 5 |
| Site countries | United States |
Patient-friendly overview of this study: eichor.com/study/NCT03592264.
Eichor generates a preliminary site-risk snapshot for NCT03592264 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Solid Tumor trials
← Eichor home · All tracked trials · Solid Tumor studies · Weekly briefs
